Cytodyn Inc. cash flow statement CYDY

In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, Cytodyn Inc. used $7.7 million of cash from operations, down 215.3% from the same quarter a year earlier.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Aug 31, 2026
Q1 FY2027
Aug 31, 2026
Q4 FY2026
May 31, 2026
Q3 FY2026
Feb 28, 2026
Q2 FY2026
Nov 30, 2025
Q1 FY2026
Aug 31, 2025
Q4 FY2025
May 31, 2025
Q3 FY2025
Feb 28, 2025
Q2 FY2025
Nov 30, 2024
Operating
Depreciation and amortization
—
0
0
+0.0%
0
-20.0%
0
+125.0%
—
0
+0.0%
0
-28.6%
0
-50.0%
Stock-based compensation
2
+19.3%
1
+192.7%
1
+37.4%
0
+30.9%
0
-65.9%
0
+31.6%
1
+27.2%
0
-60.9%
1
-6.1%
Operating cash flow
-23
-35.3%
-8
-215.3%
-5
+12.9%
-6
-11.4%
-4
-21.3%
-2
-145.0%
-6
-243.2%
-5
-112.2%
-4
-43.3%
Investing
Investing cash flow
—
0
—
—
—
—
—
—
—
Financing
Financing cash flow
30
+2672.5%
12
+10209.9%
1
-3.1%
16
+77004.8%
0
-0
-101.3%
1
-66.1%
0
-99.4%
0
-100.0%
Change in cash
Net change in cash
7
+145.1%
5
+275.3%
-4
+15.4%
11
+316.3%
-4
-21.3%
-3
-117.0%
-4
-351.1%
-5
-479.9%
-4
-94.0%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CYDY (OTC)
Fiscal year ends
May 31
Incorporated in
DE
Headquarters
Vancouver, WA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1175680
Former names
CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.